These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 2665848)

  • 1. Development of an asexual blood stage malaria vaccine.
    Moreno A; Patarroyo ME
    Blood; 1989 Aug; 74(2):537-46. PubMed ID: 2665848
    [No Abstract]   [Full Text] [Related]  

  • 2. Towards a malaria vaccine: what is in sight?
    del Giudice G
    Allergol Immunopathol (Madr); 1991; 19(3):129-35. PubMed ID: 1799171
    [No Abstract]   [Full Text] [Related]  

  • 3. Cutting edge: a new tool to evaluate human pre-erythrocytic malaria vaccines: rodent parasites bearing a hybrid Plasmodium falciparum circumsporozoite protein.
    Persson C; Oliveira GA; Sultan AA; Bhanot P; Nussenzweig V; Nardin E
    J Immunol; 2002 Dec; 169(12):6681-5. PubMed ID: 12471098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of malaria vaccines.
    Perrin LH; Simitsek P; Srivastava I
    Trop Geogr Med; 1988 Jul; 40(3):S6-21. PubMed ID: 3055567
    [No Abstract]   [Full Text] [Related]  

  • 5. Pre-erythrocytic immunity to Plasmodium falciparum: the case for an LSA-1 vaccine.
    Kurtis JD; Hollingdale MR; Luty AJ; Lanar DE; Krzych U; Duffy PE
    Trends Parasitol; 2001 May; 17(5):219-23. PubMed ID: 11323304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pre-erythrocytic malaria vaccines: towards greater efficacy.
    Hill AV
    Nat Rev Immunol; 2006 Jan; 6(1):21-32. PubMed ID: 16493425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Merozoite selection of erythrocytes by age and the induction of protective immunity.
    Brown KN; Carlsson J; Jarra W
    Blood Cells; 1990; 16(2-3):313-8. PubMed ID: 2096982
    [No Abstract]   [Full Text] [Related]  

  • 8. Studies in owl monkeys leading to the development of a synthetic vaccine against the asexual blood stages of Plasmodium falciparum.
    Rodriguez R; Moreno A; Guzman F; Calvo M; Patarroyo ME
    Am J Trop Med Hyg; 1990 Oct; 43(4):339-54. PubMed ID: 2240362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of preerythrocytic and blood-stage malaria vaccines can be assessed in small sporozoite challenge trials in human volunteers.
    Roestenberg M; de Vlas SJ; Nieman AE; Sauerwein RW; Hermsen CC
    J Infect Dis; 2012 Aug; 206(3):319-23. PubMed ID: 22615322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Localization of the ring-infected erythrocyte surface antigen (RESA) of Plasmodium falciparum in merozoites and ring-infected erythrocytes.
    Brown GV; Culvenor JG; Crewther PE; Bianco AE; Coppel RL; Saint RB; Stahl HD; Kemp DJ; Anders RF
    J Exp Med; 1985 Aug; 162(2):774-9. PubMed ID: 3894564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Malaria vaccines.
    Romero P
    Curr Opin Immunol; 1992 Aug; 4(4):432-41. PubMed ID: 1388845
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Production of human monoclonal antibodies against asexual erythrocytic stages of Plasmodium falciparum.
    Monjour L; Desgranges C; Alfred C; Ploton I; Karabinis A
    Lancet; 1983 Jun; 1(8337):1337-8. PubMed ID: 6134126
    [No Abstract]   [Full Text] [Related]  

  • 13. Generation of Plasmodium falciparum parasite-inhibitory antibodies by immunization with recombinantly-expressed CyRPA.
    Favuzza P; Blaser S; Dreyer AM; Riccio G; Tamborrini M; Thoma R; Matile H; Pluschke G
    Malar J; 2016 Mar; 15():161. PubMed ID: 26979066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasmodium falciparum pre-erythrocytic stage vaccine development.
    Molina-Franky J; Cuy-Chaparro L; Camargo A; Reyes C; Gómez M; Salamanca DR; Patarroyo MA; Patarroyo ME
    Malar J; 2020 Feb; 19(1):56. PubMed ID: 32013956
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The first field trials of the chemically synthesized malaria vaccine SPf66: safety, immunogenicity and protectivity.
    Amador R; Moreno A; Valero V; Murillo L; Mora AL; Rojas M; Rocha C; Salcedo M; Guzman F; Espejo F
    Vaccine; 1992; 10(3):179-84. PubMed ID: 1557934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The real difficulties for malaria sporozoite vaccine development: nonresponsiveness and antigenic variation.
    Good MF; Kumar S; Miller LH
    Immunol Today; 1988 Nov; 9(11):351-5. PubMed ID: 3076406
    [No Abstract]   [Full Text] [Related]  

  • 17. Cross-reactive antigenic determinants present on different Plasmodium falciparum blood-stage antigens.
    Mattei D; Berzins K; Wahlgren M; Udomsangpetch R; Perlmann P; Griesser HW; Scherf A; Müller-Hill B; Bonnefoy S; Guillotte M
    Parasite Immunol; 1989 Jan; 11(1):15-29. PubMed ID: 2467248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Irradiated sporozoite vaccine induces HLA-B8-restricted cytotoxic T lymphocyte responses against two overlapping epitopes of the Plasmodium falciparum sporozoite surface protein 2.
    Wizel B; Houghten RA; Parker KC; Coligan JE; Church P; Gordon DM; Ballou WR; Hoffman SL
    J Exp Med; 1995 Nov; 182(5):1435-45. PubMed ID: 7595214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of a peptide sequence of the 25 kD surface protein of Plasmodium falciparum recognized by transmission-blocking monoclonal antibodies: implications for synthetic vaccine development.
    van Amerongen A; Sauerwein RW; Beckers PJ; Meloen RH; Meuwissen JH
    Parasite Immunol; 1989 Jul; 11(4):425-8. PubMed ID: 2674864
    [No Abstract]   [Full Text] [Related]  

  • 20. A synthetic vaccine protects humans against challenge with asexual blood stages of Plasmodium falciparum malaria.
    Patarroyo ME; Amador R; Clavijo P; Moreno A; Guzman F; Romero P; Tascon R; Franco A; Murillo LA; Ponton G
    Nature; 1988 Mar; 332(6160):158-61. PubMed ID: 2450281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.